4.5 Article

Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait

期刊

出版社

WILEY
DOI: 10.1002/jum.16341

关键词

adverse events; children; contrast-enhanced ultrasound; sickle cell disease; sickle cell trait; ultrasound contrast agents

向作者/读者索取更多资源

There has been an increase in pain-related adverse events with the use of UCA Definity in adults. No studies have investigated the incidence of similar adverse events with UCA Lumason or Optison yet. Our experience suggests that the use of Lumason and Optison for contrast-enhanced ultrasound exams in children with sickle cell disease is safe.
Ultrasound contrast agent (UCA) use is increasing. Recent isolated reports observed a rise in pain-related adverse events with the intravenous administration of the UCA Definity in adults with sickle cell disease. To date, no studies have investigated the incidence of similar adverse events with UCA Lumason or Optison. We describe our experience regarding the safety of Lumason and Optison in children with sickle cell disease and trait who underwent contrast-enhanced ultrasound exams in our department with intravenous, intravesical, and other intracavitary routes. No pain-related or other adverse events were observed in this pediatric population with any route of UCA administration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据